Brief: Halozyme Therapeutics Outlook FY Revenue USD 1,385-1,400 Million
17/02/2026 23:50
Feb 17 (Reuters) - Halozyme Therapeutics Outlook FY revenue USD 1,385-1,400 million.
Recent news on Halozyme Therapeutics
See all newsUS RESEARCH ROUNDUP-BlackRock, Evercore, Goldman Sachs
Halozyme wins court order to block Merck's injected Keytruda in select European markets (updated)
US STOCKS ON THE MOVE-Halozyme, Moderna, Merck
U.S. STOCKS ON THE MOVE-Halozyme, BKV, AppFolio
Halozyme wins court order to block Merck's injected Keytruda in select European markets